Similar articles

• Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.

  Van Echo DA, Diggs CH, Scoltock M, Wiernik PH. Van Echo DA, et al. Cancer Treat Rep. 1980 Feb-Mar;64(2-3):339-42. Cancer Treat Rep. 1980. PMID: 7407767
• Phase II study of PALA in advanced large bowel carcinoma.

  Rubin J, Purvis J, Britell JC, Hahn RG, Moertel CG, Schutt AJ. Rubin J, et al. Cancer Treat Rep. 1981 Mar-Apr;65(3-4):335-6. Cancer Treat Rep. 1981. PMID: 6453645 No abstract available.
• Phase II evaluation of PALA in patients with metastatic lung cancer.

  Creagan ET, Eagan RT, Fleming TR, Frytak S, Nichols WC, Ingle JN, Kvols LK. Creagan ET, et al. Cancer Treat Rep. 1981 Mar-Apr;65(3-4):356-7. Cancer Treat Rep. 1981. PMID: 7237459 No abstract available.
• Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.

  Grem JL, King SA, O'Dwyer PJ, Leyland-Jones B. Grem JL, et al. Cancer Res. 1988 Aug 15;48(16):4441-54. Cancer Res. 1988. PMID: 3293772 Review. No abstract available.
• [Chemotherapy of metastasizing cancers of the colon and rectum].

  Piedbois P, Lévy E, Le Bourgeois JP, Buyse M. Piedbois P, et al. Ann Chir. 1993;47(6):480-3. Ann Chir. 1993. PMID: 7692804 Review. French. No abstract available.